Brief: Shanghai Junshi Biosciences Says Acceptance Of NDA For Senaparib
25/08/2023 16:06
Aug 25 (Reuters) - Shanghai Junshi Biosciences Co Ltd
688180.SS :
* ACCEPTANCE OF NDA FOR SENAPARIB AS MAINTENANCE TREATMENT
AFTER
FIRST-LINE THERAPY IN PATIENTS WITH ADVANCED OVARIAN CANCER
Further company coverage: 688180.SS
((reuters.briefs@thomsonreuters.com;))
Recent news on Shanghai Junshi Biosciences
See all newsBrief: Shanghai Junshi Biosciences Q3 Net Loss At 170.9 Million Yuan
Brief: Shanghai Junshi Biosciences Q3 Net Loss At 170.9 Million Yuan
Brief: Shanghai Junshi Biosciences Receives Supplemental Drug Approval From NMPA
Brief: Shanghai Junshi Biosciences's Shareholder Plans To Cut Stake
Brief: Shanghai Junshi Biosciences Gets NMPA Acceptance Notice Of Supplemental Application For Toripalimab